U.S. Markets close in 1 hr 5 mins

Is Allergan (AGN) a Great Stock for Value Investors?

Zacks Equity Research

Value investing is easily one of the most popular ways to find great stocks in any market environment. After all, who wouldn’t want to find stocks that are either flying under the radar and are compelling buys, or offer up tantalizing discounts when compared to fair value? 

One way to find these companies is by looking at several key metrics and financial ratios, many of which are crucial in the value stock selection process. Let’s put Allergan plc AGN stock into this equation and find out if it is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks:

PE Ratio

A key metric that value investors always look at is the Price to Earnings Ratio, or PE for short. This shows us how much investors are willing to pay for each dollar of earnings in a given stock, and is easily one of the most popular financial ratios in the world. The best use of the PE ratio is to compare the stock’s current PE ratio with: a) where this ratio has been in the past; b) how it compares to the average for the industry/sector; and c) how it compares to the market as a whole.

On this front, Allergan has a trailing twelve months PE ratio of 11.6, as you can see in the chart below:

This level actually compares pretty favorably with the market at large, as the PE for the S&P 500 stands at about 20.53. If we focus on the long-term PE trend, Allergan’s current PE level puts it below its midpoint of 15.19 over the past five years. Moreover, the current level stands well below the highs for the stock, suggesting that it can be a solid entry point.

Further, the stock’s PE also compares favorably with the Zacks Medical sector’s trailing twelve months PE ratio, which stands at 23.24. At the very least, this indicates that the stock is relatively undervalued right now, compared to its peers.

We should also point out that Allergan has a forward PE ratio (price relative to this year’s earnings) of just 11.36, which is higher than the current level. So, it is fair to expect an increase in the company’s share price in the near term.

P/CF Ratio

An often overlooked ratio that can still be a great indicator of value is the price/cash flow metric. This ratio doesn’t take amortization and depreciation into account, so can give a more accurate picture of the financial health in a business. This is a preferred metric to some valuation investors because cash flows are (a) generally less prone to manipulation by the company’s management, and (b) are less affected by variation in accounting policies between different companies.

The ratio is generally applied to find out whether a company’s stock is overpriced or underpriced with reference to its cash flows generation potential compared with its competitors. However, it is not commonly used for cross-industry comparison, as the average price to cash flow ratio varies from industry to industry.

In this case, Allergan’s P/CF ratio of 9 is lower than the Zacks Medical – Generic Drugs industry average of 11.88, which indicates that the stock is somewhat undervalued in this respect.

Broad Value Outlook

In aggregate, Allergan currently has a Value Score of B, putting it into the top 40% of all stocks we cover from this look. This makes Allergan a solid choice for value investors, and some of its other key metrics make this pretty clear too. 

What About the Stock Overall?

Though Allergan might be a good choice for value investors, there are plenty of other factors to consider before investing in this name. In particular, it is worth noting that the company has a Growth Score of B and a Momentum Score of D. This gives AGN a Zacks VGM score — or its overarching fundamental grade — of B. (You can read more about the Zacks Style Scores here >>)

Meanwhile, the company’s recent earnings estimates have been robust at best. The current quarter has seen two estimates go higher in the past sixty days compared to none lower, while the full year estimate has seen one up and none down in the same time period. 

This has had a positive impact on the consensus estimate though as the current quarter consensus estimate has risen by 2.2% in the past two months, while the full year estimate has inched higher by 0.3%. You can see the consensus estimate trend and recent price action for the stock in the chart below:

Allergan plc Price and Consensus

Allergan plc Price and Consensus

Allergan plc price-consensus-chart | Allergan plc Quote

This somewhat bullish trend is why the stock has just a Zacks Rank #2 (Buy) and why we are looking for outperformance from the company in the near term. 

Bottom Line

Allergan is an inspired choice for value investors, as it is hard to beat its incredible lineup of statistics on this front. Further, a strong industry rank (among Top 44% of more than 250 industries) instills our confidence. However, over the past two years, the Zacks Medical – Generic Drugs industry has clearly underperformed the broader market, as you can see below:

So, value investors might want to wait for analyst sentiment to turn around in this name first, but once that happens, this stock could be a compelling pick. 

Free: Zacks’ Single Best Stock Set to Double

Today you are invited to download our latest Special Report that reveals 5 stocks with the most potential to gain +100% or more in 2020. From those 5, Zacks Director of Research, Sheraz Mian hand-picks one to have the most explosive upside of all.

This pioneering tech ticker had soared to all-time highs and then subsided to a price that is irresistible. Now a pending acquisition could super-charge the company’s drive past competitors in the development of true Artificial Intelligence. The earlier you get in to this stock, the greater your potential gain.

See 5 Stocks Set to Double>>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Allergan plc (AGN) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research